Tackling Complications of Coronavirus Infection with Quercetin: Observations and Hypotheses

Palghadmal, Shital Balasaheb; Kulkarni, Prajakta; Makadia, Vishal; Deshmukh, Mahesh Jagannath; Gondhale, P. S.; Padmanabhan, Sriram

doi:10.14218/erhm.2021.00015

Cited by 1 publication

(1 citation statement)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug developers are making efforts to consider drug repurposing as one of the more appealing choices for addressing the sudden and abrupt advent of SARS-CoV-2 that includes allopathic drugs such as Remdesivir, Dexamethasone, and Tocilizumab (Venkateshan 2021 ), Emodin, Omipalisib, and Tipifarnib (Jang et al 2021 ; Ng et al 2021 ) and selected herbal drugs (Palghadmal et al 2021 ; Padmanabhan 2021 ; Khan and Al-Balushi 2021 ). Other tested medications, such as Chloroquinine, Hydroxychloroquine, and the Lopinavir-Ritonavir combination, have been withdrawn (Paul and Biswas 2021 ) due to inconsistent treatment reports.…”

Section: Discussionmentioning

confidence: 99%

A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19

Kulkarni¹,

Padmanabhan²

2022

Biotechnol Lett

Self Cite

View full text Add to dashboard Cite

Purpose In the wake of SARS-CoV-2’s global spread, human activities from health to social life to education have been affected. Favipiravir and Molnupiravir exhibited novel hexokinase inhibition and we discuss advantages of this property in their COVID-19 inhibition potential. Methods This paper describes molecular docking data of human hexokinase II with Favipiravir, Cyan 20, Remdesivir, 2DG, and Molnupiravir along with hexokinase inhibition assays. Results Favipiravir, an antiviral drug previously cleared for treating the flu and ebola, has shown some promise in early trials to treat COVID-19. We observed potent human hexokinase inhibiting potential of Favipiravir (50%) as against 4% and merely 0.3% hexokinase inhibition with Molnupiravir and 2 Deoxy d glucose at 0.1 mM concentration supported by molecular docking studies. Conclusion Favipiravir could continue to be part of the COVID-19 treatment regimen due to its resistance to host esterases, hexokinase inhibition potential and proven safety through human trials.

show abstract